Bisodac-HF

Bisoprolol fumarate

Stable chronic heart failure w/ reduced systolic left ventricular function in addition to ACE inhibitors, diuretics & optional cardiac glycosides. 5 & 10 mg: HTN, CHD (angina pectoris).

Stable chronic heart failure 1.25 mg once daily on 1st wk, 2.5 mg once daily on 2nd wk, 3.75 mg once daily on 3rd wk, 5 mg once daily on 4th-7th wk, 7.5 mg once daily on 8th-11th wk then 10 mg once daily for maintenance treatment. Max: 10 mg once daily. HTN or angina pectoris Initially 5 mg once daily, may be increased to 10 mg once daily. Max: 20 mg once daily.

May be taken with or without food: Swallow whole, do not chew.

Hypersensitivity. Acute heart failure or during episodes of heart failure decompensation requiring IV therapy, cardiogenic shock, 2nd or 3rd degree AV block w/o pacemaker, sick sinus syndrome, SA block, symptomatic bradycardia & hypotension, severe bronchial asthma or COPD, severe forms of peripheral arterial occlusive disease or Raynaud's syndrome, untreated phaeochromocytoma, metabolic acidosis.

Allergic reactions. DM w/ extremely fluctuating blood glucose, 1st degree AV block, Prinzmetal's angina, peripheral arterial occlusive disease, psoriasis or history of psoriasis. Bronchial asthma or other COPD diseases; phaeochromocytoma, IDDM, restrictive cardiomyopathy, congenital heart disease, hemodynamically relevant organic valvular heart disease; heart failure & MI w/in 3 mth. May masked symptoms of thyrotoxicosis. Strict fasting. Patients undergoing general anaesth; ongoing desensitization therapy. May affect ability to drive & use machines. Severe renal & hepatic impairment. Pregnancy. Not recommended during lactation. Not recommended in childn.

Bradycardia. Worsening of preexisting heart failure; dizziness, headache; GI complaints eg, nausea, vomiting, diarrhoea, constipation; feeling of coldness or numbness in extremities, hypotension; asthenia, fatigue.

Profound hypotension & AV block w/ verapamil- & diltiazem-type Ca antagonists. Decreased central sympathetic tonus w/ centrally-acting antihypertensive drugs eg, clonidine, methyldopa, moxonodine, rilmenidine. Increased risk of hypotension w/ dihydropyridine-type Ca antagonists eg, nifedipine, antihypertensive agents & other drugs w/ BP-lowering potential eg, TCAs, barbiturates, phenothiazines. Potentiated AV conduction time & increased -ve inotropic effect w/ class I antiarrhythmic drugs eg, disopyramide, quinidine. Potentiated AV conduction time w/ class III antiarrhythmic drugs eg, amiodarone. Additive systemic effects w/ topical β-blockers. Increased AV conduction time & risk of bradycardia w/ parasympathomimetic drugs. Intensified blood sugar-lowering effect w/ insulin & oral antidiabetics. Attenuated reflex tachycardia & increased risk of hypotension w/ anaesth agents. Reduced heart rate & increased AV conduction time w/ digitalis glycosides. Reduced hypotensive effects by NSAIDs. Reduced effects w/ β-sympathomimetic agents eg, isoprenaline, dobutamine. Increased BP & exacerbated intermittent claudication w/ β- & α-adrenoceptors eg, noradrenaline & adrenaline. Severe postural hypotension w/ moxisylyte. Increased risk of bradycardia w/ mefloquine. Enhanced hypotensive effects w/ MAOIs (except MAO-B inhibitors).

Beta-Blockers

C07AB07 - bisoprolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.

B